small molecule

INPEFA

SOTAGLIFLOZIN

Loss of exclusivityOctober 2030latest FDA-listed patent expiry

CompanyLexicon Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	INPEFA
Active ingredient	SOTAGLIFLOZIN
Strength	200MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	May 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
8217156	October 2030	substance, product
8476413	May 2028	substance, product
7781577	May 2028	substance, product

Regulatory exclusivity

Code	Expires
NCE	May 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Lexicon Pharmaceuticals